Accelerate the implementation of new preventive medical countermeasure manufacturing technologies across multiple platform processes by addressing workforce and technology issues that U.S. and global manufacturers and suppliers face and establishing a Center of Excellence for Vaccine Analytics and Assays.
Accelerate the production of innovative preventive medical countermeasures by ensuring that both U.S.-based and global countermeasure manufacturers and suppliers have adequate support to implement advanced manufacturing and product characterization processes.
Objective: Develop a facility and equipment available for NIIMBL members to assess techniques and facilitate training and knowledge sharing
Objective: Evaluate next-generation sequencing (NGS) as a rapid alternative assay for in vivo and in vitro adventitious virus testing for vaccine safety
Preventive Medical Countermeasures Program Kickoff held at NIIMBL headquarters
First Preventive Medical Countermeasures Program Steering Committee Meeting
AstraZeneca
Cytiva
Genentech, Inc.
MilliporeSigma/EMD Serono
NIIMBL
Pfizer, Inc.
Access more program information, including:
Learn more about how being a member of NIIMBL can grant you and your company access to NIIMBL-led programs and other collaboration opportunities.